![](https://ml.globenewswire.com/media/b52a171f-57dc-424d-8112-8d32405cff41/small/denali-t-logo-02-jpg.jpg)
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) ...
Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued improvement in hearing, cognition and adaptive behavior Long-term safety data with median follow-up of two years, …